Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
FATE THERAPEUTICS INC | Chief R&D Officer | Common Stock | 358K | $2.78M | $7.77 | Jul 29, 2024 | Direct |
FATE THERAPEUTICS INC | Chief R&D Officer | Stock Option (Right to Buy) | 450K | $1.23M | $2.73 | Feb 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
FATE | FATE THERAPEUTICS INC | Jul 29, 2024 | 1 | $0 | 4 | Jul 31, 2024 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Feb 1, 2024 | 1 | $0 | 4 | Feb 2, 2024 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Jan 9, 2024 | 1 | -$49.4K | 4 | Jan 10, 2024 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Feb 6, 2023 | 1 | $0 | 4 | Feb 7, 2023 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Jan 12, 2023 | 2 | $580 | 4 | Jan 13, 2023 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Jan 10, 2023 | 1 | -$57.2K | 4 | Jan 11, 2023 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Jul 7, 2022 | 3 | -$519K | 4 | Jul 8, 2022 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Jul 6, 2022 | 5 | -$236K | 4 | Jul 7, 2022 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Mar 14, 2022 | 7 | -$708K | 4 | Mar 15, 2022 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Jan 25, 2022 | 2 | $0 | 4 | Jan 27, 2022 | Chief Research & Development Officer |
FATE | FATE THERAPEUTICS INC | Jan 11, 2022 | 2 | -$222K | 4 | Jan 13, 2022 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Jan 10, 2022 | 2 | -$260K | 4 | Jan 12, 2022 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Dec 13, 2021 | 7 | -$1.12M | 4 | Dec 14, 2021 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Nov 19, 2021 | 1 | $0 | 4 | Nov 22, 2021 | Chief R&D Officer |
FATE | FATE THERAPEUTICS INC | Sep 13, 2021 | 5 | -$1.59M | 4 | Sep 14, 2021 | Chief Development Officer |
FATE | FATE THERAPEUTICS INC | Jun 14, 2021 | 7 | -$2.16M | 4 | Jun 16, 2021 | Chief Development Officer |